https://markets.businessinsider.com/news/stocks/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-a-second-generation-fungerp-candidate-for-invasive-fungal-infections-1034150593
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for...
JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to o...
https://stemminnesota.com/article/846036173-scynexis-announces-multiple-presentations-highlighting-data-from-its-second-generation-fungerp-scy-247-at-the-12th-congress-on-trends-in-medical
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp,...
data fromsecond generationannouncesmultiplepresentations